Ganitumab (AMG 479; 1 mg/dose; i.p; Nave and tumor-bearing mice) inhibits IGF1-induced activation of mIGF1R in murine lungs[1].
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3[1].
| Animal Model: | Nave and tumor-bearing mice[1] |
| Dosage: | 1 mg/dose |
| Administration: | Intraperitoneal injection |
| Result: | Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth. |
| Animal Model: | Male athymic nude mice[1] |
| Dosage: | 300 μg/dose |
| Administration: | Intraperitoneal injection, twice per week for a total of five doses |
| Result: | Had significantly higher serum glucose levels than hIgG1-pretreated mice.
Increased serum levels of mIGF1, mIGFPB3 and mGH.
|
| Animal Model: | Female athymic nude mice[1] |
| Dosage: | 300 μg/dose |
| Administration: | Intraperitoneal injection, twice per week for a total of five doses |
| Result: | Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls. |
